Drug combination outperforms chemotherapy in acute myeloid leukemia trial
A US clinical trial found a drug mix extended disease control and reduced hospital stays for acute myeloid leukemia patients.
A recent US clinical trial has revealed that a drug combination outperformed traditional chemotherapy for patients with acute myeloid leukemia, according to Asharq. The trial, conducted by Mass General Brigham Cancer Center in Massachusetts, found that the combination of azacitidine and venetoclax prolonged disease control and reduced hospital stays compared to intensive chemotherapy treatments.
Over twice as long, patients receiving azacitidine and venetoclax achieved treatment success before cancer recurrence or disease progression, as opposed to those who received the more intensive chemotherapy regimen. This drug combination's effectiveness extended beyond cancer control, with patients experiencing fewer severe infections and bleeding complications.
Written by urgent.news from Ajel English's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
